Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Net Resources International

07:14 EST 19th February 2018 | BioPortfolio

Here are the most relevant search results for "Net Resources International" found in our extensive news archives from over 250 global news sources.

More Information about Net Resources International on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Net Resources International for you to read. Along with our medical data and news we also list Net Resources International Clinical Trials, which are updated daily. BioPortfolio also has a large database of Net Resources International Companies for you to search.

Showing News Articles 1–25 of 545 from Net Resources International

Monday 5th February 2018

Leukaemia drug may be repurposed to fight other cancers

New research from Arizona State University’s (ASU) Biodesign Institute has found that leukaemia drug ibrutinib, marketed by Janssen under the...Read More... The post Leukaemia drug may be repurposed to fight other cancers appeared first on Drug Development Technology.

Sunday 4th February 2018

miRagen reports positive Phase l result in trial of MRG-106

miRagen Therapeutics has reported positive outcomes from its Phase l clinical trial of MRG-106 to treat patients with mycosis fungoides...Read More... The post miRagen reports positive Phase l result in trial of MRG-106 appeared first on Drug Development Technology.

Syndax to begin Phase Ib study of durvalumab and SNDX-6352

Syndax Pharmaceuticals has entered a non-exclusive agreement with AstraZeneca to start a Phase Ib trial of durvalumab in combination with...Read More... The post Syndax to begin Phase Ib study of durvalumab and SNDX-6352 appeared first on Drug Development Technology.

Tetra receives Health Canada approval for Phase lll trial of PPP001

Tetra Bio-Pharma has secured a no objection letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada for a clinical...Read More... The post Tetra receives Health Canada approval for Phase lll trial of PPP001 appeared first on Drug Development Technology.

Friday 2nd February 2018

Clinical trials for oncology biosimilars: for which indications can we expect approvals?

Over the past few years, biosimilars have been a hot topic in autoimmunity, and development has recently gained significant momentum...Read More... The post Clinical trials for oncology biosimilars: for which indications can we expect approvals? appeared first on Drug Development Technology.

Pfizer axes Phase I myeloperoxidase inhibitor but retains NASH programme

On January 30, Pfizer provided its 2017 financial results along with updates to its pipeline. As anticipated, the pharma giant...Read More... The post Pfizer axes Phase I myeloperoxidase inhibitor but retains NASH programme appeared first on Drug Development Technology.

Pfizer axes Phase I myeloperoxidase inhibitor but retains NASH program

On January 30, Pfizer provided its 2017 financial results along with updates to its pipeline. As anticipated, the pharma giant...Read More... The post Pfizer axes Phase I myeloperoxidase inhibitor but retains NASH program appeared first on Drug Development Technology.

Thursday 1st February 2018

Deals this week: Onconova Therapeutics, Humorigin Biotechnology, Zosano Pharma

Onconova Therapeutics Inc plans to raise $13.66m through a public offering of 8.65 million shares priced at $1.58 a unit....Read More... The post Deals this week: Onconova Therapeutics, Humorigin Biotechnology, Zosano Pharma appeared first on Drug Development Technology.

Panacea ends enrolment in Phase l trial of PAN-301-1

Panacea Pharmaceuticals has completed enrolling patients in a Phase l clinical trial to evaluate the safety and immunogenicity of PAN-301-1...Read More... The post Panacea ends enrolment in Phase l trial of PAN-301-1 appeared first on Drug Development Technology.

Vertex to initiate Phase lll study of VX-659 and VX-445

US-based biotechnology company Vertex Pharmaceuticals Incorporated is set to begin a Phase lll study of VX-659 and VX-445 under two...Read More... The post Vertex to initiate Phase lll study of VX-659 and VX-445 appeared first on Drug Development Technology.

Imago secures FDA IND approval for Phase l/ll trial of IMG-7289

Imago BioSciences has received approval from the US Food and Drug Administration (FDA) for the company’s investigational new drug (IND)...Read More... The post Imago secures FDA IND approval for Phase l/ll trial of IMG-7289 appeared first on Drug Development Technology.

Phase III trials lead in Australia

Figure 1: Australian clinical trials by phase. During an analysis of 3,199 clinical trials in Australia from 2012 to 2016,...Read More... The post Phase III trials lead in Australia appeared first on Drug Development Technology.

Cancer ‘vaccine’ eliminates tumours in mice

A two-pronged immunotherapy approach can eliminate all traces of cancer in mice, according to a study by the Stanford University...Read More... The post Cancer ‘vaccine’ eliminates tumours in mice appeared first on Drug Development Technology.

Wednesday 31st January 2018

Zogenix ends enrolment in second Phase lll trial of ZX008

Zogenix has completed enrolling patients for its second Phase lll clinical trial, which is designed to assess ZX008 (low-dose fenfluramine)...Read More... The post Zogenix ends enrolment in second Phase lll trial of ZX008 appeared first on Drug Development Technology.

Gemphire begins Phase lla trial of gemcabene for paediatric NAFLD

Gemphire Therapeutics has started a Phase lla proof-of-concept (PoC) clinical trial to evaluate gemcabene as a treatment for paediatric nonalcoholic...Read More... The post Gemphire begins Phase lla trial of gemcabene for paediatric NAFLD appeared first on Drug Development Technology.

Kiadis Pharma doses last patient in Phase II trial of ATIR101

Kiadis Pharma has dosed the last patient in its Phase II trial evaluating the safety and efficacy of two doses...Read More... The post Kiadis Pharma doses last patient in Phase II trial of ATIR101 appeared first on Drug Development Technology.

Increased screening for neuropathy in diabetic patients could lead to early diagnosis

Diabetes is one of the most common non-communicable diseases globally, and is a lifelong condition that causes a person’s blood...Read More... The post Increased screening for neuropathy in diabetic patients could lead to early diagnosis appeared first on Drug Development Technology.

Vaccitech is developing a potential breakthrough flu vaccine

Vaccitech, a spin-out company from the University of Oxford, is developing a universal vaccine that can be used for swine...Read More... The post Vaccitech is developing a potential breakthrough flu vaccine appeared first on Drug Development Technology.

Tuesday 30th January 2018

Mallinckrodt enrols first patient for Phase lV trial of HP Acthar Gel

Mallinckrodt has enrolled the first patient in its Phase lV trial to further evaluate the efficacy of HP Acthar Gel...Read More... The post Mallinckrodt enrols first patient for Phase lV trial of HP Acthar Gel appeared first on Drug Development Technology.

Innate Pharma and MedImmune to conduct Phase I/II oncology trial

French biotech company Innate Pharma has formed a clinical trial collaboration with AstraZeneca’s research and development arm MedImmune to combine...Read More... The post Innate Pharma and MedImmune to conduct Phase I/II oncology trial appeared first on Drug Development Technology.

Corbus receives funds for Phase llb trial of lenabasum

Corbus Pharmaceuticals has secured a development award of up to $25m from Cystic Fibrosis Foundation to support its Phase llb...Read More... The post Corbus receives funds for Phase llb trial of lenabasum appeared first on Drug Development Technology.

Takeda, Zinfandel end Phase III TOMMORROW trial for Alzheimer’s Disease

Takeda and its partner, Zinfandel, have announced that the investigation of Actos (pioglitazone) in the global Phase III TOMMORROW trial,...Read More... The post Takeda, Zinfandel end Phase III TOMMORROW trial for Alzheimer’s Disease appeared first on Drug Development Technology.

Portola’s factor Xa inhibitor reversal agent AndexXa remains on hold

The FDA has extended its timeline for reviewing Portola Pharmaceuticals’ AndexXa (andexanet alfa), a reversal agent for Xa inhibitor anticoagulants....Read More... The post Portola’s factor Xa inhibitor reversal agent AndexXa remains on hold appeared first on Drug Development Technology.

Japan has highest proportion of uveitis cases with an unknown etiology

Figure 1: diagnosed prevalent cases of uveitis by etiology type, both sexes, all ages, 2016. Uveitis is inflammation of the...Read More... The post Japan has highest proportion of uveitis cases with an unknown etiology appeared first on Drug Development Technology.

Monday 29th January 2018

SillaJen begins Phase I/II trial of Pexa-Vec for colon cancer

South Korean firm SillaJen has started patient enrolment in a Phase I/II clinical trial of its clinical candidate pexastimogene devacirepvec...Read More... The post SillaJen begins Phase I/II trial of Pexa-Vec for colon cancer appeared first on Drug Development Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks